Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | LevelStock.com: Stellar Pharmaceuticals Receives European Approval for NeoVisc(R) Single DoseLevelStock.com is an investment community providing news alerts in the Small Cap markets.
By: LevelStock.com NeoVisc(R) Single Dose is a 6mL pre-filled syringe of sterile 1.0% sodium hyaluronate solution used for the temporary replacement of synovial fluid in osteoarthritic knee joints. The product is administered in a single dose directly into the affected knee joint. Both the NeoVisc(R) Single Dose (1 x 6mL) and the original NeoVisc(R) (3 x 2mL) are now available for sale in European Union. Osteoarthritis (OA) affects approximately 85 million people in the G7 countries and is expected to increase to 122 million by 2017. In terms of market size, researchers have estimated the value of the global OA therapeutics market to be valued at approximately $5 billion in 2009. The value of this market is expected to reach $9.6 billion by 2017. This significant growth in market size is primarily attributed to the high incidence and prevalence of the disease and the high prescription rates of the currently approved products. Arnold Tenney, Stellar’s President and Chief Executive Officer, stated, “This approval is a significant milestone in Stellar’s global licensing strategy, as OA is the most common joint disease, affecting the vast majority of the population by age 70. Recent census publications indicate that Europe has 19 of the world’s 20 oldest countries in terms of population age. With the NeoVisc(R) Triple Dose product already being sold throughout Eastern Europe, the addition of the NeoVisc(R) Single Dose product provides flexibility and greater access for our distributors in these large, growing markets. In addition, the Company is actively searching for new licensing opportunities in other large markets such as the United States, China and Japan.” About Stellar Pharmaceuticals Inc. Stellar has developed and is marketing direct in Canada, and in countries around the world through out-license agreements, three products based on its core polysaccharide technology: NeoVisc(R) and NeoVisc(R) Single Dose, for the symptomatic treatment of osteoarthritis; Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company’s business including increased competition; About LevelStock.com We are an investor community and investors relations website specializing in emerging growth stocks in today's Hot Sectors and providing a platform of services for SmallCap, MicroCap, NanoCap Companies. We encourage everyone to join our social media sites: Free Subscription For Our Newsletters: FaceBook: http://www.facebook.com/ Twitter: http://twitter.com/ LevelStock.com is not a registered investment advisor or broker-dealer. The information here is believed to be reliable, but not guaranteed to be accurate by LevelStock.com Please be advised that the information contained may or may not be complete and is solely for informational purposes only. Please read our full disclaimer for complete risks and disclosures http://www.levelstock.com/ End
Account Email Address Disclaimer Report Abuse
|
|